Literature DB >> 25209863

Gender differences in adenine-induced chronic kidney disease and cardiovascular complications in rats.

Vishal Diwan1, David Small2, Kate Kauter3, Glenda C Gobe2, Lindsay Brown4.   

Abstract

Gender contributes to differences in incidence and progression of chronic kidney disease (CKD) and associated cardiovascular disease. To induce kidney damage in male and female Wistar rats (n = 12/group), a 0.25% adenine diet for 16 wk was used. Kidney function (blood urea nitrogen, plasma creatinine, proteinuria) and structure (glomerular damage, tubulointerstitial atrophy, fibrosis, inflammation); cardiovascular function (blood pressure, ventricular stiffness, vascular responses, echocardiography) and structure (cardiac fibrosis); plasma testosterone and estrogen concentrations; and protein expression for oxidative stress [heme oxygenase-1, inflammation (TNF-α), fibrosis (transforming growth factor-β), ERK1/2, and estrogen receptor-α (ER-α)] were compared in males and females. Adenine-fed females had less decline in kidney function than adenine-fed males, although kidney atrophy, inflammation, and fibrosis were similar. Plasma estrogen concentrations increased and plasma testosterone concentrations decreased in adenine-fed males, with smaller changes in females. CKD-associated molecular changes in kidneys were more pronounced in males than females except for expression of ER-α in the kidney, which was completely suppressed in adenine-fed males but unchanged in adenine-fed females. Both genders showed increased blood pressure, ventricular stiffness, and cardiac fibrosis with the adenine diet. Cardiovascular changes with adenine were similar in males and females, except males developed concentric, and females eccentric cardiac hypertrophy. In hearts from adenine-fed male and female rats, expression of ER-α and activation of the ERK1/2 pathway were increased, in part explaining changes in cardiac hypertrophy. In summary, adenine-induced kidney damage may be increased in males due to the suppression of ER-α.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  ERK1/2; cardiovascular disease; chronic kidney disease; estrogen receptor-α; inflammation

Mesh:

Substances:

Year:  2014        PMID: 25209863     DOI: 10.1152/ajprenal.00676.2013

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  29 in total

1.  Cisplatin nephrotoxicity as a model of chronic kidney disease.

Authors:  Mingjun Shi; Kathryn L McMillan; Junxia Wu; Nancy Gillings; Brianna Flores; Orson W Moe; Ming Chang Hu
Journal:  Lab Invest       Date:  2018-06-01       Impact factor: 5.662

2.  IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.

Authors:  Jianmin Chen; Julius E Kieswich; Fausto Chiazza; Amie J Moyes; Thomas Gobbetti; Gareth S D Purvis; Daniela C F Salvatori; Nimesh S A Patel; Mauro Perretti; Adrian J Hobbs; Massimo Collino; Muhammad M Yaqoob; Christoph Thiemermann
Journal:  J Am Soc Nephrol       Date:  2016-05-06       Impact factor: 10.121

3.  The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.

Authors:  Megan L Noonan; Pu Ni; Rafiou Agoro; Spencer A Sacks; Elizabeth A Swallow; Jonathan A Wheeler; Erica L Clinkenbeard; Maegan L Capitano; Matthew Prideaux; Gerald J Atkins; William R Thompson; Matthew R Allen; Hal E Broxmeyer; Kenneth E White
Journal:  J Bone Miner Res       Date:  2021-03-10       Impact factor: 6.741

4.  Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin.

Authors:  Mark R Hanudel; Brian Czaya; Shirley Wong; Maxime Rappaport; Shweta Namjoshi; Kristine Chua; Grace Jung; Victoria Gabayan; Bo Qiao; Elizabeta Nemeth; Tomas Ganz
Journal:  Kidney Int       Date:  2021-11-25       Impact factor: 10.612

5.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21

6.  Extra-Large Gα Protein (XLαs) Deficiency Causes Severe Adenine-Induced Renal Injury with Massive FGF23 Elevation.

Authors:  Julia Matthias; Qiuxia Cui; Lauren T Shumate; Antonius Plagge; Qing He; Murat Bastepe
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

7.  Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice.

Authors:  Shrikant R Mulay; Jonathan N Eberhard; Victoria Pfann; Julian A Marschner; Murthy N Darisipudi; Christoph Daniel; Simone Romoli; Jyaysi Desai; Melissa Grigorescu; Santhosh V Kumar; Birgit Rathkolb; Eckhard Wolf; Martin Hrabě de Angelis; Tobias Bäuerle; Barbara Dietel; Carsten A Wagner; Kerstin Amann; Kai-Uwe Eckardt; Peter S Aronson; Hans Joachim Anders; Felix Knauf
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-13

8.  Cellular and Molecular Mechanisms of Kidney Injury in 2,8-Dihydroxyadenine Nephropathy.

Authors:  Barbara Mara Klinkhammer; Sonja Djudjaj; Uta Kunter; Runolfur Palsson; Vidar Orn Edvardsson; Thorsten Wiech; Margret Thorsteinsdottir; Sverrir Hardarson; Orestes Foresto-Neto; Shrikant R Mulay; Marcus Johannes Moeller; Wilhelm Jahnen-Dechent; Jürgen Floege; Hans-Joachim Anders; Peter Boor
Journal:  J Am Soc Nephrol       Date:  2020-02-21       Impact factor: 10.121

9.  A Novel Model of Chronic Kidney Disease in Rats: Dietary Adenine in Combination with Unilateral Nephrectomy.

Authors:  Cristina Muñoz Abellán; Sandra Mangold-Gehring; Sina Micus; Gerald Beddies; Andreas Moritz; Elke Hartmann; Waldemar Lehmann; Frank Eitner
Journal:  Kidney Dis (Basel)       Date:  2019-01-16

10.  Skeletal myopathy in CKD: a comparison of adenine-induced nephropathy and 5/6 nephrectomy models in mice.

Authors:  Kyoungrae Kim; Erik M Anderson; Trace Thome; Guanyi Lu; Zachary R Salyers; Tomas A Cort; Kerri A O'Malley; Salvatore T Scali; Terence E Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2021-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.